Literature DB >> 19770328

Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.

Lorenzo Mannelli1, Sooah Kim, Cristina H Hajdu, James S Babb, Timothy W I Clark, Bachir Taouli.   

Abstract

OBJECTIVE: The purpose of this study was to compare, with histopathologic examination of the liver explant as the reference standard, diffusion-weighted MRI with contrast-enhanced subtraction MRI in the assessment of necrosis of hepatocellular carcinoma (HCC) after trans arterial chemoembolization (TACE).
MATERIALS AND METHODS: The cases of 21 patients with HCC who underwent MRI after TACE were evaluated. Two independent observers calculated the apparent diffusion coefficient (ADC) of HCC and measured percentage tumor necrosis on subtraction images. The ADCs of necrotic and viable tumor tissues were compared. ADC and percentage necrosis on subtraction images were correlated with percentage necrosis found at pathologic examination. Receiver operating characteristics analysis was performed on the diagnosis of complete tumor necrosis.
RESULTS: Twenty-eight HCCs (mean diameter, 2.3 cm) were evaluated. There were significant differences between the ADC of viable tissue and that of necrotic tumor tissue (1.33 +/- 0.41 vs 2.04 +/- 0.38 x 10(-3) mm(2)/s, p < 0.0001). There was significant moderate correlation between ADC and the pathologic finding of percentage necrosis (r = 0.64, p < 0.001) and significant strong correlation between subtraction image and pathologic percentage necrosis (r = 0.89-0.91, depending on the phase; p < 0.001). In the diagnosis of complete tumor necrosis, ADC had an area under the curve, sensitivity, and specificity of 0.85, 75%, and 87.5% compared with 0.82-0.89, 100%, and 58.3-79.1% for subtraction imaging (p > 0.5 between ADC and subtraction imaging).
CONCLUSION: Compared with diffusion-weighted imaging, contrast-enhanced MRI with subtraction technique had more significant correlation with the histopathologic findings in the evaluation of necrosis of HCC after TACE. There was no difference, however, between the two methods in diagnosis of complete tumor necrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19770328     DOI: 10.2214/AJR.08.1461

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  49 in total

Review 1.  Noncontrast functional MRI of the kidneys.

Authors:  Lorenzo Mannelli; Jeffrey H Maki; Sherif F Osman; Hersh Chandarana; David J Lomas; William P Shuman; Ken F Linnau; Douglas E Green; Giacomo Laffi; Miriam Moshiri
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.

Authors:  Maïté Lewin; Laetitia Fartoux; Alexandre Vignaud; Lionel Arrivé; Yves Menu; Olivier Rosmorduc
Journal:  Eur Radiol       Date:  2010-08-05       Impact factor: 5.315

3.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

Review 4.  Imaging appearance of treated hepatocellular carcinoma.

Authors:  Francesco Agnello; Giuseppe Salvaggio; Giuseppe Cabibbo; Marcello Maida; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Hepatol       Date:  2013-08-27

5.  Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis.

Authors:  Alessandro Cucchetti; Matteo Serenari
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

Review 6.  Cancer concepts and principles: primer for the interventional oncologist-part I.

Authors:  Ryan Hickey; Michael Vouche; Daniel Y Sze; Elias Hohlastos; Jeremy Collins; Todd Schirmang; Khairuddin Memon; Robert K Ryu; Kent Sato; Richard Chen; Ramona Gupta; Scott Resnick; James Carr; Howard B Chrisman; Albert A Nemcek; Robert L Vogelzang; Robert J Lewandowski; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2013-06-25       Impact factor: 3.464

7.  Diffusion-weighted imaging of the liver: usefulness of ADC values in the differential diagnosis of focal lesions and effect of ROI methods on ADC measurements.

Authors:  João Pedro Filipe; Luís Curvo-Semedo; João Casalta-Lopes; Maria Cristina Marques; Filipe Caseiro-Alves
Journal:  MAGMA       Date:  2012-10-06       Impact factor: 2.310

8.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

9.  Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.

Authors:  Michele Di Martino; Luca Saba; Sandro Bosco; Massimo Rossi; Kirchin A Miles; Rossella Di Miscio; Concetta Valentina Lombardo; Elisabetta Tamponi; Mario Piga; Carlo Catalano
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

10.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

Authors:  Susanne Bonekamp; Zhen Li; Jean-François H Geschwind; Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Diane Reyes; Timothy M Pawlik; David Bonekamp; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.